CION Ameerpet
Maintenance therapy is the part of ovarian cancer treatment that is paid for month after month, often for two years, and it is the part families are least prepared for. The monthly figure is real, it is large, and it varies more than any other line on the bill. This page sets out what drives it, what is usually covered, and what to insist on in writing before the first month is bought.
If you have typed PARP inhibitor cost India into a search bar, you are usually somewhere specific: chemotherapy has finished, the scan is clear, and someone has just told you that the next stage of treatment is a tablet taken every day for about two years. The relief and the arithmetic arrive in the same conversation.
Here is the honest starting figure. CION publishes an indicative range of ₹50,000 to ₹1,20,000 a month for PARP-inhibitor-class maintenance on its ovarian cancer treatment page. At the upper end of what is quoted across Hyderabad — a higher dose level, or an originator brand rather than a licensed generic-equivalent supply — the monthly figure reaches roughly ₹2 to ₹3 lakh. That spread is not an error. It is the single most important thing to understand about this cost.
Run the arithmetic over a planned two-year course and the published range comes to about ₹12 lakh to ₹29 lakh, and considerably more above it. These are indicative ranges from published CION pages, not a quotation for you. But they explain why the test result that decides whether you should be on maintenance at all matters more here than on any other line of an ovarian cancer bill.
Unlike surgery, this is not one invoice. It is dispensed month after month for a planned course, so a small difference in the monthly figure becomes a very large difference over two years.
Several drugs sit in the PARP-inhibitor class and they are not priced alike. Dose level, and whether a licensed generic-equivalent supply exists, change the figure substantially.
A germline BRCA panel costs a fraction of one month of maintenance. Knowing your BRCA and HRD status before you start is the cheapest decision in the pathway.
PARP-inhibitor-class maintenance is not priced by how advanced the cancer is. It is priced by the month — and whether it is worth that price depends almost entirely on a test result. NCCN recommends that every woman diagnosed with epithelial ovarian cancer is offered germline BRCA1 and BRCA2 testing, with somatic tumour testing including homologous recombination deficiency (HRD) status where germline testing is negative, precisely because those results identify who gains most from maintenance therapy and who gains least. In India a germline BRCA panel costs a small fraction of a single month of maintenance. Testing before starting is the cheapest decision in the whole treatment pathway, and the one most often skipped. Source: NCCN Clinical Practice Guidelines in Oncology — Ovarian Cancer; Society of Gynecologic Oncology clinical practice statement on genetic testing in ovarian cancer.
The tablet is the largest line but it is not the only one. An estimate that names only the drug is an incomplete estimate, and the difference shows up in month two.
| Line item | Indicative range | What moves it |
|---|---|---|
| PARP-inhibitor-class maintenance, per month | ₹50,000 – ₹1,20,000 on CION’s published indicative range; up to roughly ₹2–3 lakh at the top of what is quoted in Hyderabad | Which drug in the class is prescribed, the dose level, and whether an originator brand or a licensed generic-equivalent supply is dispensed. |
| Germline BRCA1 and BRCA2 panel | ₹15,000 – ₹35,000, once | Panel size and laboratory. Done once, and the result never expires. It also tells your sisters and daughters whether cascade testing is worth arranging. |
| Tumour HRD testing | Priced per laboratory — ask for the quote in writing | Used mainly where germline BRCA testing is negative. It costs more than a BRCA panel and takes longer to report, so order it early rather than after chemotherapy ends. |
| CA-125 monitoring | ₹500 – ₹1,500 per test | How often it is repeated. During maintenance it is usually checked at review visits rather than continuously. |
| Blood counts and liver and kidney checks | Routine pathology rates, monthly at first | Anaemia and low platelet counts are the commonest reason for a dose change in this class, so early monitoring is closer together and then spaces out. |
| Review consultations | First consultation free at CION; scheduled reviews thereafter | How often you are seen, and whether reviews can be done at a centre near you rather than requiring travel to one city hospital. |
*Indicative ranges published on CION pages. They are not a quotation, and no figure here should be treated as your price. For the wider picture including surgery and chemotherapy, see ovarian cancer treatment cost in Hyderabad.
Two women with the same diagnosis, treated in the same city, can be quoted figures that differ several-fold. None of that is arbitrary. Each of these is worth asking about by name.
The PARP-inhibitor class contains several drugs. They are taken on different schedules, they are supplied in different strengths, and they are not priced alike. Your oncologist chooses between them on clinical grounds — your test result, your blood counts and kidney function, whether this is first-line maintenance or maintenance after a recurrence — and that clinical choice sets the price band before cost is even discussed.
Dose level matters as much as the choice of drug. A lower daily dose usually means fewer or smaller tablets dispensed, which usually means a smaller monthly bill. Ask which drug in the class is planned and at what starting dose, because a quote given without those two facts is a guess.
This is the largest single swing in the figure. Where a licensed generic-equivalent formulation is available in India for the drug you have been prescribed, the monthly cost falls substantially compared with the originator brand. Where it is not, it does not.
Ask directly: is there a licensed generic-equivalent supply of this specific drug at this strength, and is the pharmacy quoting for the brand or the generic? Put the question to your oncologist rather than to a pharmacy counter, because whether a substitution is appropriate for you is a clinical judgement, not a purchasing one.
Dose reductions are common in this class and they are made for medical reasons — most often anaemia, a low platelet count, or fatigue and nausea that will not settle. They are a normal part of maintenance treatment and not a sign that it is failing. Practice supports continuing at a reduced dose rather than stopping altogether.
A reduced dose does usually reduce the monthly cost, because fewer or smaller tablets are dispensed. That is a genuine effect and worth knowing. What it is not is a reason to reduce your own dose. Tell your oncology team if cost is the pressure, because the options they can offer are better than the one you would choose alone.
First-line PARP-inhibitor-class maintenance is usually planned for about two years rather than continued indefinitely. Maintenance after a recurrence may be planned differently, sometimes continuing for as long as it is working and tolerated. The intended duration is what turns a monthly figure into a total, so ask for it at the start.
Treatment can also finish earlier — if side effects cannot be managed even with a dose reduction, or if the disease returns while you are taking it. Plan around the intended course, but understand that the real total is only known at the end of it.
Take-home oral cancer drugs are the hardest part of a treatment plan to get covered, and it catches families out. Many indemnity policies pay readily for chemotherapy given in a hospital day-care chair and treat tablets dispensed for use at home under different terms. Scheme packages such as Aarogyasri and PMJAY are built around procedures, and long-course oral maintenance carries its own specific rules at empanelled centres.
None of that means you are not covered. It means the answer has to be checked against your policy wording and your scheme eligibility before you buy the first month, and confirmed in writing. A verbal assurance at a counter is not cover. Ask the hospital insurance desk to obtain pre-authorisation naming the specific drug and the intended duration.
Manufacturer-run patient assistance programmes exist for several long-course oncology drugs in India, and eligibility usually turns on documented household income, the prescription itself, and continuing treatment at a registered centre. Some operate as a supply arrangement rather than a discount, so what you receive and what you pay are worth clarifying separately.
These programmes are not advertised at the pharmacy counter. Ask your oncologist or the hospital pharmacy whether one applies to the drug you have been prescribed, what documents are needed, and how long approval takes — so you are not left with a gap between finishing chemotherapy and starting maintenance.
None of these involve anyone acting in bad faith. They are the predictable gaps between how a long-course oral drug is prescribed and how it is paid for.
Monitoring bloods, CA-125 and review visits are part of the running cost. Ask for the estimate to name them, not just the tablets.
BRCA and HRD results decide how much benefit the monthly cost buys. Order them early, so the result guides the decision instead of arriving after it.
Dose changes are common in the first weeks. A large advance purchase at the starting dose can strand stock you no longer need.
Cover for oral drugs used at home often differs from cover for chemotherapy given in hospital. Confirm the specific drug and duration in writing first.
It changes the treatment without changing the plan, and your team cannot account for what they do not know. Tell them cost is the problem instead.
A figure quoted verbally cannot be checked against an insurer, a scheme or a second opinion. Ask for it on paper before anything is dispensed.
If the monthly figure is out of reach, say so plainly at the consultation rather than after the first month. There are more options on the table at that point — a different drug in the class, a licensed generic-equivalent supply, an assistance programme, or a considered decision that maintenance is not the right use of your family’s resources — and every one of them is better discussed than discovered.
A 45-minute consultation, a review of your test results and treatment plan, and an itemised estimate that names every line — the drug, the monitoring and the reviews. No cost for the first visit, and no obligation to treat with us.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Bring your BRCA or HRD report and any quote you have been given. We will tell you plainly what it buys, what it does not, and whether it is the right decision for your situation.
Every figure on this page is indicative. Yours is not, and it takes about one consultation and two phone calls to establish it properly.
Germline BRCA testing from a blood sample, and tumour HRD testing where the germline result is negative. Order these during chemotherapy rather than after it, because HRD reporting takes time and the result should guide the maintenance decision, not follow it. CION delivers genetic counselling and BRCA and HRD testing in-house.
These are the two facts that set the price band. Ask your oncologist to name the planned drug and the starting dose, and whether a licensed generic-equivalent supply exists for it at that strength. Without both, any quote you are given is an estimate of an estimate.
It should name the monthly drug cost, the monitoring bloods, CA-125 checks and review visits, and the intended duration of the course. CION provides a written itemised estimate before treatment starts — ask for the same wherever you are treated, so you can compare like with like.
Take the estimate to the hospital insurance desk and ask for pre-authorisation for the specific drug and duration, in writing. Separately, ask whether you are eligible under Aarogyasri or PMJAY at an empanelled centre, and what the scheme rules are for long-course oral drugs.
Ask your oncologist or the hospital pharmacy whether a manufacturer patient assistance programme covers the prescribed drug, what documents are required, and how long approval takes. Ask separately about EMI, which is available on selected treatment packages at CION.
Set a date — commonly after the first two or three months — to review tolerance, dose and cost together. Maintenance is a long commitment and it should be reviewed as one, rather than renewed by default each time the pack runs out.
Bring your pathology report, your BRCA or HRD result if you have one, and any quote you have already been given. That is enough for a specialist to tell you what your own figure looks like, in a single consultation.
Maintenance therapy is given to delay the cancer coming back. That is the claim the evidence supports, and it is the claim worth paying for. It is not a cure, it does not remove the need for follow-up, and no one can tell you in advance how long the delay will be for you. A page that promised otherwise would be selling you something.
The size of the benefit is graded, and it is graded by your test result. Women with a BRCA1 or BRCA2 pathogenic variant gain the most. Women whose tumour shows homologous recombination deficiency without a BRCA variant gain a meaningful amount. Women negative for both gain the least, and for them the decision is genuinely finely balanced — which is exactly why the test belongs before the prescription rather than after it.
You will find stage-specific and subtype-specific survival percentages quoted online alongside maintenance costs. Treat them carefully. Published figures are historical, they average across substages and subtypes, and they mix women who had complete surgery with women who did not. They describe groups, not you. The useful conversation is about your own result, your own tolerance and your own circumstances, and it takes longer than a percentage does.
Delays recurrence after a response to platinum-based chemotherapy, for a planned course, in women selected by test result.
It is not a cure, not a guarantee against recurrence, and not a substitute for follow-up scans and clinical review.
The clearer your BRCA and HRD result, the clearer the decision. An unclear result plus a large monthly figure is the combination that most deserves a second opinion — start with the complete ovarian cancer guide.
Your first consultation at CION is free and runs to about 45 minutes — long enough to go through the pathology report, the test results and the quote you have been given, line by line. Every case that raises a question is discussed at a tumour board rather than decided by one doctor alone, and a written, itemised cost estimate is provided before treatment begins.
Maintenance therapy is delivered in-house. So is chemotherapy, and so are genetic counselling and BRCA and HRD testing, across more than 35 centres in Telangana and Andhra Pradesh — which matters for a two-year treatment, because monthly monitoring near where you live costs less in time and travel than repeated trips to one city hospital.
Being straightforward about the rest: cytoreductive and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT imaging are coordinated with specialist partner centres and may be billed there rather than by CION. If any of those sit in your pathway, they belong in your total, and we would rather set that out at the start than have you discover it on an invoice. For the full picture see ovarian cancer treatment cost in Hyderabad.
Free and unhurried. Bring your reports and any quote you have been given — that is enough to get a real answer in one visit.
A written estimate naming the drug, the monitoring and the reviews before treatment starts. Decisions for healing, not billing.
Chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered by CION. Surgery and HIPEC are coordinated with specialist partner centres.
Monthly bloods and review visits close to home across Telangana and Andhra Pradesh, which is what makes a two-year course practical.
CION publishes an indicative range of ₹50,000 to ₹1,20,000 a month for PARP-inhibitor-class maintenance therapy. At the upper end of what is quoted across Hyderabad, where a higher dose level or an originator brand rather than a licensed generic-equivalent supply is dispensed, the figure reaches roughly ₹2 to ₹3 lakh a month. That is a wide spread, and it is driven by which drug in the class is prescribed, the dose level, and the brand or generic question. Neither figure is a quotation for you. Ask your oncologist to name the planned drug and starting dose, then ask for a written itemised estimate that also includes the monitoring bloods and review visits, because those run alongside the tablets for the whole length of the course.
Because several different things are being quoted. The PARP-inhibitor class contains more than one drug, and they are taken on different schedules and supplied at different strengths, so they are not priced alike. Dose level changes how many tablets are dispensed each month. Whether a licensed generic-equivalent formulation is available in India for your specific prescription is the single largest swing in the figure. And some quotes cover only the drug while others include the blood monitoring, CA-125 checks and review visits that go with it. When you compare two figures, check that they name the same drug, the same dose and the same list of items. Otherwise you are comparing two different treatments and learning nothing from the difference.
Sometimes, and it needs checking in advance rather than assuming. Take-home oral cancer drugs are treated differently from chemotherapy given in a hospital day-care chair under many indemnity policies, and that difference catches families out at exactly the wrong moment. Scheme cover under Aarogyasri and PMJAY is built around procedure packages, and long-course oral maintenance has its own specific rules at empanelled centres. The practical step is to take a written, itemised estimate to the hospital insurance desk and ask for pre-authorisation naming the specific drug and the intended duration, and separately to have your scheme eligibility checked. Get both answers in writing before the first month is bought. CION accepts most major cashless insurers, is empanelled for Aarogyasri, and offers EMI on selected packages.
First-line PARP-inhibitor-class maintenance is usually planned for about two years rather than continued indefinitely. On the published indicative range of ₹50,000 to ₹1,20,000 a month, that arithmetic comes to roughly ₹12 lakh to ₹29 lakh over the full course, and considerably more where the monthly figure sits above that range. Add the one-off cost of BRCA and HRD testing, and the running cost of monitoring bloods and review visits. Two things can change the total. Doses are often reduced for side effects, which usually reduces the monthly cost, and treatment sometimes finishes early if it cannot be tolerated or the disease returns. Ask for the intended duration at the start, because that is what turns a monthly figure into a plan you can budget for.
Do not do either without telling your oncologist. Dose reductions in this class are common and entirely normal, but they are decided on medical grounds, usually anaemia, a low platelet count, or fatigue and nausea that will not settle. A reduced dose does generally mean a smaller monthly bill, which is a real effect, but changing your own dose quietly means your team is monitoring a treatment you are not actually taking. If cost is the pressure, say so at the consultation. There is far more on the table at that point than there is later, including a different drug in the class, a licensed generic-equivalent supply, a patient assistance programme, or a considered decision to stop and move to surveillance instead.
The benefit is graded rather than all-or-nothing. Women with a BRCA1 or BRCA2 pathogenic variant gain the most from PARP-inhibitor-class maintenance. Women whose tumour shows homologous recombination deficiency without a BRCA variant gain a meaningful amount. Women negative for both gain the least, and there the decision is genuinely finely balanced against a large monthly cost sustained over about two years. That is not a reason to dismiss it, and it is not a reason to assume it either. It is the reason the testing belongs before the prescription. If you have been offered maintenance without a BRCA or HRD result, ask why, and ask what the plan would be if the result came back negative.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing. A written, itemised cost estimate is provided before treatment begins, and every case that raises a question is reviewed at a tumour board. Cytoreductive surgery and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT imaging are coordinated with specialist partner centres and may be billed there, which we say upfront rather than leaving it to be discovered later. Bring your reports and any quote you have been given.